


IFW



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**


Applicant : Klaveness, et al.  
App. No : 10/583,829  
Filed : June 21, 2006  
For : MODULATORS OF PERIPHERAL 5-HT  
RECEPTORS  
Examiner : Unassigned  
Art Unit : Unassigned

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 25, 2006

(Date)

  
Eric S. Furman, Ph.D., Reg. No. 45,664

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450


Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing twelve (12) references.
  - (X) Enclosing eight (8) references.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

  
Eric S. Furman, Ph.D.  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT

Applicant: Klaveness, et al.

App. No : 10/583,829

Filed : June 21, 2006

For : MODULATORS OF PERIPHERAL 5-HT RECEPTORS

Examiner : Unassigned

Art Unit : Unassigned

## CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 25, 2006

(Date)

  
Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing twelve (12) references to be considered by the Examiner. Also enclosed are eight (8) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.


This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON &amp; BEAR, LLP

Dated: 9/25/06

By:   
Eric S. Furman, Ph.D.  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/583,829
	Filing Date	June 21, 2006
	First Named Inventor	Jo Klaveness
	Art Unit	Unassigned
	Examiner	Unassigned
	Attorney Docket No.	PLOUG19.001APC

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,552,004	04-02-2003	Elazhary, et al.	
	2	6,624,163	09-23-2003	Flohr, et al.	
	3	6,632,827	10-14-2003	McCullough, et al.	
	4	2003/0019386	01-30-2003	Lloyd, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	5	EP 1 149 832	10-31-2001	Hokuriku Seiyaku Co., Ltd.		
	6	JP 11-292846	10-26-1999	Hokurika Pharmaceutical Co., Ltd.		
	7	WO 96/10027	04-04-1996	JANSSEN PHARMACEUTICA, et al.		
	8	WO 01/93849	12-13-2001	ARYX THERAPEUTICS		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	9	International Search Report for International Application No. PCT/NO2004/000399 dated 8/17/2005.	
	10	Muller-Lissner, et al. "Tegaserod, a 5-HT <sub>4</sub> receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation." Aliment Pharmacol Ther. 15:1655-1666 (2001).	
	11	Mutschler, et al. "Arzneimittelwirkungen." WYG, Stuttgart. 462-466 (2001).	
	12	Sanger, et al. "SB-207266: 5-HT <sub>4</sub> receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models." Neurogastroenterol. Mot. 10:271-279 (1998).	

2959408 sma092506

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.